Amgen today announced it will acquire privately held, clinical stage biotechnology company Teneobio in a deal that includes a $900 million upfront cash payment, plus future contingent milestone payments. Complements $AMGN Antibody Research Capabilities Across Therapeutic Areas.
FDA Approves MacroGenics Drug Margenza For Breast Cancer With Chemotherapy
Biopharmaceutical company MacroGenics Announced Wednesday FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer following Phase 3 clinical trials. Product launch anticipated in March of 2021
AstraZeneca Lung Cancer Drug Tagrisso 89% Survival Rate After Two Years
AstraZeneca on Thursday announced rresults of a clinical trial of its genetically targeted lung cancer drug Tagrisso with an “overwhelming benefit”. $AZN said after two years 89% of the lung cancer patients given Tagrisso following surgery were alive without a recurrence of their tumors.
Allogene Therapy Treatment Shows Complete Remission in Lymphoma Cancer Patients
Allogene Therapeutics on Wednesday released data on the success of it’s off-the-shelf CAR-T cell therapy for an aggressive form of B-cell lymphoma blood cancer. The results showing some patients experienced complete remission. The stock $ALLO surged over 50% on the release.